Description
Front-line venetoclax monotherapy for blastic plasmacytoid dendritric cell neoplasm
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: Front-line venetoclax monotherapy for blastic plasmacytoid dendritric cell neoplasm
€3.03
Related products
-
Article: INTRODUCTION
€3.03 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: INTRODUCTION
€3.03 Add to cart -
Article: Highlights in urologic cancer
€3.03 Add to cart
Reviews
There are no reviews yet.